Voltaflex

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Voltaflex

Quick Facts about Voltaflex (Diclofenac)

Property Description
Active ingredient Diclofenac (commonly as Diclofenac sodium)
Form Varies (e.g., tablet, gel, solution for injection)
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
General purpose Pain relief and inflammation reduction
Origin Synthetic (phenylacetic acid derivative)

What Type of Medicine is Voltaflex? (NSAID Classification and Origin)

Voltaflex is a synthetic pharmaceutical preparation whose core active ingredient is Diclofenac, classifying it as a Nonsteroidal Anti-inflammatory Drug (NSAID). The active substance, Diclofenac, is chemically identified as a phenylacetic acid derivative. This designation places it in the class of potent, non-narcotic agents that modify the body's inflammatory response. The substance has established primary actions including pain relief, inflammation reduction, and fever control. Diclofenac is recognized globally as a foundational compound exhibiting analgesic, anti-inflammatory, and antipyretic properties. The preparation is typically a single product formulation, concentrating solely on delivering the benefits of the Diclofenac component.


Diclofenac's General Purpose and Formulations

The general purpose of the Diclofenac within Voltaflex is to offer pain relief (analgesia) and inflammation reduction. It achieves this by inhibiting the synthesis of prostaglandins, powerful lipid compounds that act as key chemical mediators for pain and swelling. NSAIDs like Diclofenac primarily help by addressing the underlying inflammatory process, which is often the source of physical discomfort. For example, the drug's formulation is typically used to ease discomfort associated with common inflammatory states, such as a muscle strain or localized swelling. To accommodate varying patient needs, Voltaflex is manufactured in a wide spectrum of dosage forms, including tablets for oral intake, gels for topical application, and solutions for injection for parenteral routes. This versatility in formulation ensures that the medication can be administered appropriately to target discomfort, whether the goal is localized or systemic relief.

What side effects are possible with Voltaflex?

The safety profile of Voltaflex (Diclofenac), an NSAID, is structured by government regulatory agencies based on official classifications of adverse reactions and systemic risks. The medicine's safety data systematically organizes potential effects by frequency and System-Organ Class (SOC).

Documented Adverse Reactions

The most commonly listed adverse reactions (classified as Common in regulatory tables) generally involve the Gastrointestinal disorders SOC, including nausea, dyspepsia, abdominal pain, vomiting, and diarrhea. Other frequently documented effects include headache and dizziness from the Nervous system disorders SOC, and elevated liver enzymes from Hepatobiliary disorders.

Serious Adverse Event Warnings

Official labeling carries specific warnings regarding Serious Cardiovascular Thrombotic Events (such as myocardial infarction and stroke) and Serious Gastrointestinal Adverse Events (including bleeding, ulceration, and perforation), which are recognized risks of the NSAID class and can be fatal. These risks may increase with the duration of use and higher doses of systemic Diclofenac.

Safety Restrictions and Special Populations

Systemic use is contraindicated in individuals with established severe cardiac failure (NYHA class II–IV), existing gastrointestinal ulceration, or a history of severe allergic reactions to NSAIDs. Regulatory documents note that older adults are at a heightened risk for serious gastrointestinal adverse events. Use is generally restricted during the third trimester of pregnancy.

Safety Profile Structure

This structure ensures that the risk profile is formally communicated, defining the medicine's safety boundaries and linking the most significant risks to class-specific effects and factors like exposure and pre-existing health conditions.

Overdose and Emergency Response

The overdose profile for Voltaflex (Diclofenac) is defined by a progression of clinical effects documented in government regulatory sources. For any suspected overdose, immediate medical attention must be sought. Official documentation specifies that individuals must contact emergency services immediately.

Documented overdose presentations typically include gastrointestinal discomfort such as nausea, vomiting, epigastric pain, and possible gastrointestinal bleeding. Central Nervous System (CNS) manifestations such as drowsiness, lethargy, and headache are also noted.

Severe, life-threatening outcomes are regulator-listed and may involve acute renal failure, liver damage (hepatitis), and serious CNS events including convulsions and coma. In some cases, severe hypotension has been documented.

Management of a Diclofenac overdose is limited to symptomatic and supportive treatment; no specific antidote is documented. Supportive measures may include the use of activated charcoal or gastric lavage, depending on the timing of ingestion. Continuous hospital monitoring of vital signs, renal function, and hepatic function is required. Patients with pre-existing renal or hepatic impairment are identified in regulatory documents as populations with an increased risk for severe outcomes.

Therapeutic Uses of Voltaflex

What Voltaflex Treats: Main Uses and Benefits

Voltaflex (Diclofenac) is commonly used across domains where additional symptomatic support is needed to address symptoms related to inflammatory or irritative states. In settings marked by temporary physiological imbalance, the medication may assist with reducing the overall symptom burden.

Comprehensive Symptom Support

The medication is applicable within clinical settings that involve acute or disruptive symptom patterns and is used across areas where short-term symptom management is appropriate. It is considered relevant for managing symptoms that may become more disruptive during flare-ups and is relevant for easing symptoms related to physical discomfort.

Voltaflex is used for managing the persistent symptoms of chronic conditions such as Rheumatoid Arthritis, Osteoarthritis, and Ankylosing Spondylitis, and is applied in addressing acute episodes like pain from minor musculoskeletal sprains and strains, and specific painful states such as migraine attacks and primary dysmenorrhea.

By addressing these symptom clusters, Voltaflex may assist with maintaining functional stability and may contribute to improved day-to-day comfort during symptomatic periods.


Quick Fact: Symptom Support Domains

Context Benefit
Chronic Joint Conditions May help manage persistent stiffness and tenderness.
Acute Injury/Trauma May support the relief of sudden pain and associated swelling.
Episodic Pain Applied to ease intense pain during migraine or menstrual episodes.

Eligibility and Restrictions for Use

Voltaflex is a combination medication containing diclofenac sodium (a nonsteroidal anti-inflammatory drug or NSAID) and misoprostol (a gastroprotective agent). It is typically prescribed to patients who require long-term NSAID therapy for conditions like osteoarthritis or rheumatoid arthritis, but who are also at high risk of developing NSAID-induced stomach ulcers or gastrointestinal bleeding.

Contraindications (Who Should NOT Use Voltaflex)

Due to the components of the drug, Voltaflex is contraindicated in several groups, including:

  • Pregnant women: The misoprostol component can cause uterine rupture, abortion, premature birth, or birth defects, and therefore the drug is strictly contraindicated in pregnancy.
  • Patients with a history of allergic reactions (such as asthma, hives, or other hypersensitivity reactions) after taking aspirin or other NSAIDs.
  • Patients in the setting of coronary artery bypass graft (CABG) surgery.
  • Individuals with active gastrointestinal bleeding.
  • Patients with severe uncontrolled heart failure, established ischemic heart disease, peripheral arterial disease, or cerebrovascular disease.

Caution in Specific Populations

Careful consideration and physician oversight are necessary for elderly patients, as well as those with compromised kidney or liver function, or pre-existing hypertension (high blood pressure) or congestive heart failure.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Voltaflex (Diclofenac) defines specific interaction categories that result in mandatory restrictions or require monitoring of co-administered substances.

Pharmacodynamic and Pharmacokinetic Constraints

Interaction Type Interacting Agent Categories Official Constraint or Outcome
Additive Bleeding Risk Anticoagulants, Antiplatelet Agents, SSRIs/SNRIs Increases risk of serious gastrointestinal bleeding or hemorrhage.
Pharmacokinetic (PK) Modification Voriconazole (CYP2C9 Inhibitor) Formally increases Diclofenac plasma concentration (Cmax and AUC).
Renal Clearance Alteration Lithium, Methotrexate, Digoxin Decreases renal clearance of co-administered drug, elevating their plasma levels.
Diminished Efficacy Diuretics, ACE Inhibitors/ARBs Diclofenac may reduce the antihypertensive and natriuretic effects.

The regulatory profile strictly mandates avoidance of co-administration with other systemic Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including COX-2 selective inhibitors, due to additive undesirable effects and risk reinforcement. Furthermore, the use of alcohol is a documented factor that increases the risk for gastrointestinal bleeding. Specific Diclofenac formulations should not be taken with food as this is documented to reduce effectiveness. Caution is required when combining with Diuretics or ACE-Inhibitors in the elderly or those with compromised renal function, as this interaction is officially noted to increase the risk of worsening kidney function.

Mechanism of Action

Inhibition of the Cyclooxygenase (COX) Enzyme System

Diclofenac functions as a non-selective reversible inhibitor of the Cyclooxygenase (COX) enzymes, targeting both the constitutive COX-1 and the inducible COX-2 isoforms. This molecular action fundamentally blocks the enzyme-mediated conversion of arachidonic acid into various prostaglandins, which are critical lipid mediators in physiological signal generation. The drug accumulates in synovial fluid and tissues where it restricts these early biochemical processes.

Regulation of Peripheral and Central Signaling

The resulting reduction in prostaglandin synthesis affects two key physiological systems. Peripherally, it restricts the biochemical processes that mediate vascular permeability and localized fluid exudation at tissue injury sites. Simultaneously, it reduces the chemical sensitization of nociceptors (pain receptors), leading to an elevated threshold for the transmission of nociceptive signals. Centrally, PGE2 synthesis inhibition within the hypothalamus reverses the prostaglandin-mediated elevation of the body's internal temperature set-point, thereby modulating the physiological control of body temperature.

Dosage and Administration Information

How Voltaflex is Used: Administration Guidelines

Administration of Voltaflex (Diclofenac) varies based on the form and route. It is available for systemic use via oral, intramuscular (IM), intravenous (IV), and rectal routes, as well as for localized use via topical gels and solutions.


Dosage and Frequency

Form / Route Adult Dosing Range Frequency Pattern
Oral (IR/DR) 100 mg to 150 mg total daily dose Taken in divided doses (2 to 4 times a day)
Oral (ER) 100 mg total daily dose Taken once daily
IM/IV 75 mg per dose (max 150 mg/day) Once daily, often for short-term use only (e.g., up to 2 days)
Topical Gel Specified amounts (e.g., 2-4 grams) Applied up to 4 times daily

Procedural and Contextual Instructions

Oral forms like enteric-coated or delayed-release tablets are swallowed whole and not crushed, chewed, or split, as this alters the drug's release properties. While immediate-release tablets are generally taken with water, some specialized formulations require administration on an empty stomach. Conversely, taking the medicine with food may occur if gastrointestinal discomfort is a factor.

Parenteral forms (IV) require dilution with an approved solution (e.g., saline or glucose) before administration and are infused slowly. Intramuscular injection requires deep intragluteal injection and is generally limited to acute, short-term courses.

For older adults, usage focuses on the lowest effective dose and continuous monitoring due to altered pharmacokinetics. If a regular dose is missed, standard practice involves skipping the missed dose and returning to the regular schedule rather than taking a double dose.

Recent Clinical Evidence

The information below summarizes the types of official research evidence, such as Randomized Controlled Trials (RCTs) and comprehensive Meta-Analyses, that regulatory and scientific sources use to describe the clinical study of Voltaflex (Diclofenac). This overview is purely descriptive and contains no medical advice or therapeutic recommendations.


Evidence for Use in Chronic Joint Conditions

Voltaflex was evaluated in numerous RCTs and Meta-Analyses for conditions like Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis. These studies monitored outcomes related to physical discomfort and daily functioning (e.g., the WOMAC Index) in adult and older populations. Studies reported patterns observed in measured pain and function when compared to control groups, contributing to understanding symptom patterns over intermediate-term durations (4 to 12 weeks).


Evidence for Use in Acute Pain and Injury

Research examined the use of Voltaflex in conditions involving periods of heightened symptom activity such as Sprains and Musculoskeletal Injuries. Research relies on short-term RCTs that assessed outcomes describing episodic or acute changes. Researchers monitored the time taken for patients to report initial symptom change and tracked functional mobility. However, follow-up durations for these acute studies were typically limited to one to two weeks.


Evidence for Episodic Pain States

Voltaflex was evaluated in focused RCTs designed to examine a single-event treatment protocol for Migraine Attacks and Primary Dysmenorrhea. These studies explored outcomes related to the assessment of severe pain, tracking how symptoms changed over short periods. Research describes measurements of the reduction in symptom severity scores in trials conducted during periods of increased symptom activity.


Research Landscape and Uncertainties

Controlled trial evidence provides limited information for long-term outcomes regarding the sustained persistence of measured changes over periods exceeding one year. Data for certain high-risk patient groups remain insufficient, as core trials systematically excluded individuals with significant pre-existing cardiac or renal conditions. Furthermore, while numerous controlled studies exist, findings for certain functional outcomes were reported as mixed or statistically variable across some meta-analyses. Research is ongoing to better characterize these uncertainties.

Key Studies & References

  1. Guidelines for the management of rheumatoid arthritis: Diclofenac use

Frequently Asked Questions (FAQ)

Common questions about Voltaflex (FAQ)


Q: How long does it usually take to feel the effects of Voltaflex?

Official documents note that the time it takes to reach the maximum concentration of the active ingredient in the bloodstream, a measure of how quickly it starts working, varies based on the specific formulation. For instance, immediate-release tablets may be processed faster than delayed-release or extended-release forms.


Q: What are the most common side effects people talk about with Voltaflex?

Official regulatory lists cite adverse reactions that frequently involve the stomach and digestive system, such as nausea, abdominal discomfort, and diarrhea, as common occurrences. Other frequently documented effects from official sources include headache and dizziness from the nervous system.


Q: Does Voltaflex cause stomach upset or issues?

The medicine is a combination of two ingredients: one (diclofenac) to address pain and inflammation, and one (misoprostol) specifically included to help reduce the risk of serious stomach and intestinal side effects, such as ulcers or bleeding. Despite the protective ingredient, common digestive issues like abdominal discomfort and diarrhea are still frequently cited in regulatory safety tables.


Q: Is it okay for older people or seniors to use Voltaflex?

Official guidance requires careful consideration and monitoring for older adults, noting that they are at a heightened risk for serious gastrointestinal adverse events. Regulatory advice emphasizes using the lowest effective dose and continuous monitoring due to the potential for altered risks.


Q: Can Voltaflex be taken with blood pressure medicine?

Regulatory documents describe potential interactions with specific types of blood pressure medications, such as Diuretics and ACE Inhibitors/ARBs. These interactions may reduce the effectiveness of the blood pressure medicine or increase the risk of worsening kidney function.


Q: Are there any foods or drinks that should be avoided when using Voltaflex?

Official documents state that consuming alcohol while using this medicine is a documented factor that increases the risk for serious gastrointestinal bleeding. Additionally, some specialized tablet forms should not be taken with food, as official information documents that this can reduce the medicine's effectiveness.


Q: Are there any known issues with taking Voltaflex and alcohol?

Official regulatory information states that consuming alcohol while using this medicine is a documented factor that increases the risk for serious gastrointestinal bleeding. This risk is related to the potential for the active ingredient to irritate the digestive tract.


Q: Is it true that Voltaflex can affect the liver?

Official regulatory safety lists commonly include changes in liver enzyme levels (Hepatobiliary disorders) as a documented adverse reaction. This finding indicates that the medicine has the potential to affect liver function.


Q: Is Voltaflex safe for people with kidney problems?

Official regulatory documents require careful consideration and physician oversight for individuals with compromised kidney function. The risk is compounded by potential interactions, as the combination with certain other drugs is noted to increase the risk of worsening kidney function.


Q: Can I use Voltaflex if I have asthma or breathing issues?

The medicine is contraindicated (should not be used) in patients with a history of allergic reactions (such as asthma attacks, hives, or other severe hypersensitivity reactions) after taking aspirin or other NSAIDs. This is a critical restriction documented in regulatory information.


Q: Does Voltaflex have a 'warning label' I should know about?

Yes, official labeling carries specific, prominent warnings regarding Serious Cardiovascular Thrombotic Events (such as heart attack or stroke) and Serious Gastrointestinal Adverse Events (such as bleeding or perforation). These are recognized, class-specific risks for the type of medicine Voltaflex belongs to.


Q: Are there any rare but serious side effects to look out for?

Official documents define serious adverse events that include Serious Cardiovascular Thrombotic Events and Serious Gastrointestinal Adverse Events, which can be fatal. These risks may increase with the duration of use and are formally documented in the medicine's safety profile.


Q: Can Voltaflex cause a severe allergic reaction?

Yes, regulatory documents note that the medicine is contraindicated in individuals with a history of severe allergic reactions (hypersensitivity) to aspirin or other NSAIDs. This is a crucial safety restriction based on the potential for a serious, whole-body response.


Q: What happens if I accidentally take two doses of Voltaflex too close together?

Official regulatory information describes a number of potential symptoms of an overdose that can include lethargy, drowsiness, nausea, vomiting, and abdominal pain. More severe symptoms like GI bleeding or kidney failure are possible. In the event of a suspected overdose, immediate professional medical assistance is necessary.


Q: Can I take other pain relievers while using Voltaflex?

Regulatory documents strictly mandate avoidance of co-administration with other systemic Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including COX-2 selective inhibitors. This restriction is in place because combining these medicines creates an increased risk for additive undesirable effects.


Q: Do you need a prescription to get Voltaflex?

The specific combination of ingredients in this medicine (diclofenac and misoprostol) is classified by regulatory authorities as a prescription medicine (or: a POM - Prescription Only Medicine). This means it can only be dispensed under the direct order of a healthcare professional.


Q: Is Voltaflex safe to use for a long time?

Official regulatory warnings describe that the risk of serious side effects, such as cardiovascular and gastrointestinal events, is associated with longer duration of use. Furthermore, regulatory research summaries indicate that evidence for sustained outcomes over long periods (exceeding one year) is often limited.


Q: Will Voltaflex show up on a standard drug test?

Official regulatory classification identifies the active ingredient as a Nonsteroidal Anti-inflammatory Drug (NSAID). It is not classified as a controlled substance and is not generally screened for on standard drug tests that look for illicit or controlled prescription drugs.


Q: Are there different strengths or types of Voltaflex available?

Regulatory documents define the medicine's availability in a wide spectrum of dosage forms, including tablets, gels, and solutions for injection. These forms come with different approved strengths and release patterns, such as immediate-release (IR) and extended-release (ER) versions.


Q: What kind of research has been done on Voltaflex?

Research evidence primarily consists of Randomized Controlled Trials (RCTs) and Meta-Analyses evaluating the medicine's use. Studies focus on measuring outcomes related to symptom patterns in chronic joint conditions (like pain and function) and monitoring episodic changes in symptom severity for acute pain and injury.


Q: Is Voltaflex habit-forming or addictive?

The active ingredient is a Nonsteroidal Anti-inflammatory Drug (NSAID) and is not classified as a controlled substance by regulatory bodies. Official regulatory documents do not list the medicine as a habit-forming or addictive substance.


Q: What is the typical length of treatment with Voltaflex?

Regulatory guidance emphasizes that the lowest effective dose should be used for the shortest duration necessary to meet the treatment goal. Specific forms, such as injections, are officially limited to short-term use.


Q: How does Voltaflex affect my ability to drive or operate machines?

Official documents advise that adverse reactions affecting the central nervous system, such as dizziness, headache, or visual disturbances, may occur. If these effects are experienced, they could influence the ability to safely drive or operate heavy machinery.


Q: What are the signs of an overdose of Voltaflex?

Official regulatory information describes potential symptoms of an overdose that can include lethargy, drowsiness, nausea, vomiting, and abdominal pain. More severe symptoms like GI bleeding or kidney failure are possible. In the event of a suspected overdose, immediate professional medical assistance is necessary.


Q: What is the difference between brand-name Voltaflex and generic versions?

Regulatory agencies classify a generic product as therapeutically equivalent if it contains the same active ingredient, has the same strength, dosage form, and route of administration, and is demonstrated to be bioequivalent to the brand-name product. This regulatory status ensures the products are expected to work in the same way.


Q: How long does Voltaflex stay in your system after stopping?

Official pharmacokinetic data indicates that the active ingredient has a relatively short elimination half-life, meaning it is quickly processed by the body. The half-life is the time it takes for half the drug to be cleared from the bloodstream.


Q: What are the major research themes discussed in scientific papers about Voltaflex?

Official research summaries focus on measuring patient outcomes related to symptom patterns in chronic joint conditions (like pain and function) and monitoring episodic changes in symptom severity for acute pain. The research also aims to characterize uncertainties, such as long-term safety.

How should Voltaflex be stored and disposed of?

Storage and Disposal Requirements

Official regulatory guidelines define specific conditions for storing Voltaflex (Diclofenac) to maintain its stability. Oral tablets must generally be stored at or below 25 C and kept away from light and excessive moisture. The topical gel formulation requires storage at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), and must be protected from freezing. For all formulations, it is a mandatory requirement to keep the medicine out of the sight and reach of children.

Disposal of unused or expired Voltaflex should follow official instructions. This often involves asking a healthcare professional or pharmacist about drug take-back programs, which is the preferred disposal method. If using household disposal, expired medicine must be mixed with an undesirable substance, sealed, and discarded in the trash, ensuring all personal information is removed from the packaging.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Voltaflex found in:

A-Z Index: